Physician profile
Katelyn Bruner
NPI 1538586417
$2,399.42
in general payments reported to CMS, 2019-2025
16 companies · $901 in 2025
The $901 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $610 · 2024: $888 · 2025: $901.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,391 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,390.97 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $423.03 | 2023-2025 | Ubrelvy, Qulipta |
| Novo Nordisk INC | $385.02 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $340.88 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $275.21 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $243.91 | 2023-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Astrazeneca Pharmaceuticals Lp | $147.87 | 2023-2025 | Farxiga, Breztri |
| Amgen INC. | $118.87 | 2024-2025 | Repatha, Otezla, Krystexxa |
| Edwards Lifesciences Corporation | $90.81 | 2025 | Sapien 3 Ultra Resilia |
| Glaxosmithkline, LLC. | $83.54 | 2024-2025 | Shingrix, Arexvy, Pediarix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.71 | 2024-2025 | Jardiance |
| Astellas Pharma US INC | $52.59 | 2025 | Veozah |
| Idorsia Pharmaceuticals US INC | $48.23 | 2023-2024 | Quviviq |
| Hologic Sales and Service, LLC | $47.62 | 2024 | Aptima |
| Exact Sciences Corporation | $34.66 | 2025 | Cologuard Collection Kit |
| Exeltis, USA INC. | $23.15 | 2024 | Slynd |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $17.32 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katelyn Bruner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.